Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Research
A ‘very detailed map’ of enzyme target in rare genetic disease
For some rare genetic diseases, the problem isn't a missing protein but the buildup of toxic molecules that the body can no longer clear away.
Marissa Russo
Nov 17, 2026 3:31pm
Fierce Pharma
AZ’s reported $10B offer for Rhythm fuels talks of a bidding war
Nov 5, 2026 9:36am
Ultragenyx shrinks workforce and axes assets to halve R&D spend
Nov 4, 2026 5:19am
Researchers may have found the culprit behind Angelman syndrome
Oct 29, 2026 7:00am
FDA’s rare disease framework aims to ‘stand the test of time’
Oct 28, 2026 3:16pm
Ambrose inks $181M deal for former Pfizer target AM-Pharma
Oct 20, 2026 2:00am